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Abstract 
Background: Although the use of corticosteroids has been linked to high incidence of weight gain, no 
data are available concerning the differences in corticosteroid use between a diverse obese population 
and non-obese individuals. The main purpose of this study was to systematically explore the use of 
corticosteroids in obese subjects compared to non-obese controls. In addition, we also explored 
self-reported marked weight gain within obese subjects. 
Methods: Two hundred seventy-four obese outpatients (median [range] BMI: 40.1 kg/m2 [30.5-67.0]), 
and 526 non-obese controls (BMI: 24.1 kg/m2 [18.6-29.9]) from two different Dutch cohort studies 
were included. Corticosteroid use at the time of clinic or research site visit for up to the preceding 
three months was recorded in detail. Medical records and clinical data were evaluated with regard to 
age and body mass index in relation to corticosteroid use, single or multiple type use, and administration 
forms. 
Results: Recent corticosteroid use was nearly twice as high for obese subjects than for non-obese 
controls (27.0% vs. 11.9% and 14.8%, both P<.001). Largest differences were found for use of local 
corticosteroids, in particular inhaled forms, and simultaneous use of multiple types. Marked weight gain 
was self-reported during corticosteroid use in 10.5% of the obese users. 
Conclusion: Corticosteroid use, especially the inhaled agents, is higher in obese than in non-obese 
individuals. Considering the potential systemic effects of also local corticosteroids, caution is warranted 
on the increasing use in the general population and on its associations with weight gain. 
Key words: corticosteroids; obesity; adverse effects. 
Introduction 
Synthetic corticosteroids are invaluable in the 
treatment of a wide range of somatic disorders and 
have shown their value in many physically 
demanding conditions. Their different administration 
routes (e.g. topical, inhaled, nasal, ocular, 
intra-articular, oral, intra-venous) encourage the use 
of these medications in both local and systemic 
disorders in which their mitigating effect on 
inflammation and the immune system is desired. The 
widespread use of corticosteroids becomes obvious in 
national surveys since it is prescribed at least 5.8 
million times annually in the 17 million-strong Dutch 
population [1], whereas in the United States 
prescription numbers reach over 40 million [2]. These 
numbers may even underestimate the total use when 








corticosteroids and the use in alternative medicine, 
since some of the non-registered herbal creams have 
been found to contain potent corticosteroids [3, 4]. In 
regard to oral corticosteroids, its use substantially 
increased with thirty percent over the past two 
decades, with a prevalence of current use around 1% 
of the population [5-7]. For inhaled corticosteroids, 
the percentage of users even doubled between 1990 
and 1997 in both the United Kingdom and the 
Netherlands [8]. 
 In addition to their therapeutic effects, 
corticosteroids are well known to induce a variety of 
adverse effects affecting virtually all body systems [9, 
10]. Corticosteroid users often experience endocrine 
and metabolic changes, in particular an increase in 
weight [11]. This is not surprising, since it is known 
that high cortisol levels can lead to increased appetite, 
(truncal) fat accumulation, and altered lipid and 
glucose metabolism [12-14]. Prolonged use, especially 
of oral corticosteroids, is notorious for inducing 
hypercortisolism related side effects and is archetypal 
for exogenous Cushing’s syndrome [15]. However, 
those systemic side effects are not confined to 
systemic use, but were also found in local use of 
corticosteroids. In a recent meta-analysis Broersen et 
al. investigated different characteristics of 
corticosteroid use and their effects on adrenal 
suppression. They found that use of nearly all forms 
of corticosteroids resulted in an increased risk of 
adrenal insufficiency [16]. The highest numbers were 
found for intra-articular injections and oral use 
(absolute risk of 52.2% and 48.7%, respectively), while 
similar numbers were also found in patients using 
multiple administration forms, including 
combinations of only local corticosteroids. These 
results indirectly indicate that also local agents result 
in high systemic corticosteroid exposure and a 
subsequent suppression of the adrenal gland function 
due to negative feedback mechanisms, irrespective of 
the route of administration, and thus potentially lead 
to weight gain and its cardiometabolic derangements.  
 Although various studies have shown an 
increasing effect of corticosteroids on body mass 
index (BMI), it still remains unknown whether there is 
a difference in overall corticosteroid use or in use of 
particular administration forms between obese and 
non-obese in the general population. Based on the 
results of the above-mentioned meta-analysis [16] and 
given the fact that weight gain is one of the most 
common undesirable effects of corticosteroid use, we 
hypothesized an overall higher user rate in obese 
subjects. Hence, in the present study we 
systematically investigated the use of corticosteroids 
in an obese outpatient population in comparison to 
two independent non-obese control cohorts. 
Moreover, in the same obese population, we also 
specifically examined if marked weight gain could be 
correlated to corticosteroid use. 
Subjects and Methods 
Obese subjects 
Two hundred eighty-two obese patients visiting 
the Obesity Center CGG of the Erasmus Medical 
Center (Rotterdam, The Netherlands) between June 
2011 and September 2015 were initially included. 
Before visiting the outpatient clinic, which is a 
multidisciplinary referral center for diagnostic testing 
and tailored treatment of obesity, all patients were 
requested to complete an extensive questionnaire 
regarding factors related to their overweight. With 
this questionnaire, we obtained data on self-reported 
marked weight gain, including questions about 
whether the patient recalled a time period where they 
experienced a marked increase in weight, and if so, if 
they suspected any triggering factor for that. The 
questionnaire also included questions concerning 
current and previous medication use, including 
specific questions about the use of corticosteroids. 
Recent corticosteroid use was defined as use at the 
time of visit and/or in the preceding three months 
and was categorized as local (topical, inhaled, nasal, 
ocular, intra-articular) or systemic (oral/intra-venous) 
use and as single or multiple type (i.e., combinations 
of different administration routes) use. All completed 
questionnaires were scrutinized by experienced 
physicians and discussed with the patient at the clinic 
visit in order to avoid incomplete information or 
misinterpretation of the questions. These 
questionnaires and electronic medical records, 
including records of the visit, were also used to assess 
weight and height. BMI was computed by dividing 
weight (kg) by height squared (m2). Patients in whom 
the time of corticosteroid use was unknown (N=8) 
were excluded from the analyses. Ethical approval 
was obtained for the present study. 
Non-obese controls 
In order to assess the use of corticosteroids in 
non-obese subjects, we included participants of two 
different Dutch cohort studies: the Lifelines and the 
Netherlands Study of Depression and Anxiety 
(NESDA) cohort.  
 The Lifelines cohort is a large population-based 
cohort study from the Northern Netherlands 
(www.lifelines.nl) [17]. Participants are observed over 
an extended period of time and are subjected to 
multiple moments of data and sample collection. One 
of the collection procedures requires the patients to 
complete a questionnaire about corticosteroid use in 
the past three months. For this study, we included a 




sample of 295 participants who had completed this 
self-report research questionnaire. In these persons, 
we assessed the same anthropometric features and 
corticosteroid-related characteristics (yes/no current 
corticosteroid use, types of administration forms, and 
single or multiple type use) as in the obese 
outpatients. 
 The other control cohort was recruited from 
NESDA, a large ongoing longitudinal cohort study 
among adult participants with a current or past 
psychopathological diagnosis together with healthy 
controls with no previous psychiatric diseases [18]. 
Here, we evaluated the clinical data and 
questionnaires of 355 psychiatrically healthy controls 
in whom the same research questionnaire as in the 
Lifelines cohort was collected [19]. In order to 
minimize recall bias with regard to corticosteroid use, 
we assessed both completed questionnaires and 
minutely detailed information about medication use 
that was checked during each visit at the research site.  
 For comparative analyses, we excluded 
participants with underweight (BMI<18.50) or obesity 
(BMI ≥30.00) from both Lifelines (control group I) and 
NESDA (control group II) cohorts, which resulted in 
the exclusion of respectively 60 (20.3%) and 61 (17.2%) 
subjects. From the latter group, also three healthy 
controls were excluded because of inconclusive data 
on corticosteroid use. Subsequently, a total number of 
526 non-obese controls (control group I, N=235; 
control group II, N=291) were enrolled in this study. 
In order to investigate if there was a relationship 
between corticosteroid use and age and whether the 
numbers of recent users between obese and non-obese 
subjects differed with age, we analyzed the 
differences between both groups in weighted 
age-tertiles. This resulted in the classification of 
persons <36 years in the first tertile, 36-49 years in the 
second, and ≥50 years in the last tertile.  
Statistical analysis 
Statistical analysis was performed with IBM 
SPPS Statistics version 21 (IBM Corp., Armonk, NY) 
and GraphPad Prism version 5.01 (GraphPad 
Software Inc., La Jolla, CA) for Windows. Differences 
in demographic and clinical characteristics were 
analyzed using Chi-square tests and ANOVA’s, when 
appropriate. Trend analysis for corticosteroid use in 
relation to age-tertiles was performed with the 
Cochran-Armitage test for trend. Logistic regression 
analyses were conducted for comparative analyses 
between the obese and the control groups and were 
adjusted for age and sex as indicated. P-values below 
0.05 were considered to indicate statistical 
significance for all analyses. 
Results 
Baseline characteristics 
The demographic and clinical characteristics of 
the three groups are summarized in Table 1. The 
average BMI in the obese group was 40.7±6.3 kg/m2 
versus 24.7±2.6 (control group I, P<.001) and 24.0±2.8 
kg/m2 (control group II, P<.001) in the non-obese 
cohorts. All groups consisted primarily of women, 
with percentages ranging from 64.9% (control group 
II) up to 75.2% (obese group). Obese participants were 
on average younger compared to control group II 
(41.5±14.3 vs. 46.7±14.9 years, P<.001) but were not 
different in age compared to control group I. 
 
 
Table 1. Demographic and clinical characteristics of study 
participants 
 Obese Non-obese 
Control group I Pdiff Control group II Pdiff 
N 274 235  291  
Sex, n (%)   .347  .008 
 Male 68 (24.8) 67 (28.5)  102 (35.1)  
 Female 206 (75.2) 168 (71.5)  189 (64.9)  
Age, years 41.5 (14.3) 42.0 (11.7) .662 46.7 (14.9) <.001 
BMI, kg/m2 40.7 (6.3) 24.7 (2.6) <.001 24.0 (2.8) <.001 
Values are presented as number (percentage) or mean (SD). Differences were 
analyzed using Chi-square tests and ANOVA’s.  
 
 
Corticosteroid use obese versus non-obese 
In the obese group, 55.8% of all patients reported 
having used any form of corticosteroids at any time 
point. Among the obese subjects, 74/274 (27.0%) 
subjects were currently using or had used 
corticosteroids in the past three months. Among the 
recent users, the inhaled and nasal agents were most 
commonly used (Table 2). Asthma, hay 
fever/rhino(-sinusitis), and psoriasis were the main 
known indications for corticosteroid use (25.7%, 8.9%, 
and 7.9%; Table 3). Recent use of corticosteroids in the 
obese group was significantly higher compared to 
non-obese from both control cohorts (11.9%, P<.001 
[control group I] and 14.8%, P<.001 [control group II]; 
Figure 1).  
 Dividing the control groups into two weight 
classes, i.e. “normal weight” (BMI 18.50–24.99) and 
“overweight” (BMI 25.00-29.99), and comparing these 
to the obese subjects still resulted in significant 
differences regarding the recent use of corticosteroids. 
Largest differences were observed between normal 
weight controls from both cohorts and the obese 
subjects (P<.001 [control group I] and P=.001 [control 
group II]; Figure 1).  
 






Figure 1. Recent corticosteroid use in obese and non-obese subjects. Analyses between the obese group and the non-obese control groups as a whole 
(black bars), or stratified for two weight classes (light gray = normal weight, dark gray = overweight) are controlled for sex and age. All asterisks depict P-values for 
the comparisons with the obese group. **P<.01, ***P<.001. 
 
Table 2. Recent use of different corticosteroid administration 




Control group I 
(N=235) 
Pdiff Control group II 
(N=291) 
Pdiff 
Local 70 (25.5%) 27 (11.5%) <.001 38 (13.1%) <.001 
 Topical 21 (7.7%) 11 (4.7%) .145 17 (5.8%) .323 
 Inhaled 38 (13.9%) 7 (3.0%) <.001 11 (3.8%) <.001 
 Nasal 23 (8.4%) 12 (5.1%) .147 15 (5.2%) .173 
 Ocular 3 (1.1%) 0 (0.0%) - 1 (0.3%) .251 
 Intra-articular 3 (1.1%) 0 (0.0%) - 0 (0.0%) - 
Systemic 
(oral/i.v.) 
7 (2.6%) 2 (0.9%) .180 8 (2.7%) .631 
Multiple types 17 (6.2%) 4 (1.7%) .015 7 (2.4%) .038 
Values are presented as number (percentage). Differences in use of each 
corticosteroid administration form between obese patients and the control groups 
were analyzed separately using logistic regression analyses adjusted for sex and 
age. Abbreviation: i.v., intra-venous. 
Table 3. Indications for recent corticosteroid use in the obese 
group. 
 Corticosteroid prescriptions (N=101) 
Asthma, n (%) 26 (25.7) 
Hay fever/rhino(-sinusitis), n (%) 9 (8.9) 
Psoriasis, n (%) 8 (7.9) 
Eczema, n (%) 7 (6.9) 
COPD, n (%) 6 (5.9) 
Nasal congestion, n (%) 3 (3.0) 
Ocular diseases*, n (%) 3 (3.0) 
Auto-immune diseases†, n (%) 2 (2.0) 
Others‡, n (%) 12 (11.9) 
Unknown, n (%) 25 (24.8) 
Values are presented as number (percentage). *Includes iridocyclitis, scleritis, and 
uveitis; †Includes cerebral vasculitis and Crohn’s disease; ‡Includes among others 
alopecia areata, nasal polyps, panhypopituitarism, and renal transplantation. 
 
 
 With regard to age-tertiles, we found 
significantly higher corticosteroid use in obese 
subjects for each age group with the smallest 
difference in the oldest tertile (mean difference per 
tertile: 14.3%, P=.005 [first tertile], 15.5%, P=.001 
[second tertile], and 11.4%, P=.039 [third tertile]; 
Figure 2). Separate trend analyses showed a 
significant trend in the non-obese group (χ21=4.520, 





Figure 2. Relation between different age groups and use of 
corticosteroids. The three age groups represent weighted age-tertiles of 
obese and the combined non-obese participants from both control groups. 
Logistic regression analyses between obese and non-obese age groups are 
adjusted for sex. *P<.05, **P<.01. Abbreviations: OB, obese; NO, non-obese. 
 
Administration routes of corticosteroids 
In the obese group, the use of local 
corticosteroids was significantly higher compared to 
both non-obese controls (25.5% vs. 11.5% [control 
group I] and 13.1% [control group II], both P<.001; 
Table 2). In addition, stratification for the different 




administration routes revealed significantly higher 
rates for inhaled corticosteroids in the obese subjects. 
There were, however, no differences in use of the 
other local corticosteroids or the systemic 
administration forms.  
 Use of multiple types of corticosteroids was 
present in 17 obese patients (6.2%). This was 
significantly higher than in the control groups I (1.7%, 
P=.015) and II (2.4%, P=.038). The majority of the 
multiple type users of both the obese and the 
non-obese groups were using at least one inhaled 
corticosteroid (88% and 73%, respectively). The 
combination of inhaled corticosteroids with at least 
one topical corticosteroid was most common in the 
obese group (47%), whereas in the non-obese controls 
inhaled forms were frequently combined with nasal 
corticosteroids (55%; Table 4). 
 
Table 4. Combination of corticosteroids in users of multiple 
types of corticosteroids. 
 Obese (N=17) Non-obese (N=11) 
Inhaled with topical, n (%) 5 (29) 1 (9) 
Inhaled with nasal, n (%) 5 (29) 4 (36) 
Inhaled with topical and nasal, n (%) 2 (12) 0 (0) 
Inhaled with nasal and oral, n (%) 1 (6) 2 (18) 
Topical with nasal, n (%) 0 (0) 2 (18) 
Others, n (%) 4 (24) 2 (18) 
Values are presented as number (percentage) within the group of multiple types 
users for the obese group and combined non-obese control group. 
 
Marked weight gain 
Of the obese subjects who reported recent or ever 
use of corticosteroids, 10.5% considered the use of 
corticosteroids as the underlying cause of a period of 
marked weight gain. The oral administration form 
was reported most frequently (12/16 subjects) as the 
triggering factor, followed by two patients who had 
previously received corticosteroid injections. Majority 
of the patients from the former administration form 
(67%) had used or were currently using prednisone 
for over 3 months continuously, two subjects had 
been prescribed prednisone for a short-term period 
(<3 months) and two patients had used it for an 
unknown duration. 
Discussion  
To the best of our knowledge, this is the first 
study to systematically examine corticosteroid use in 
a diverse sample of obese and non-obese individuals. 
Here, we have shown that the use of corticosteroids 
was significantly higher in obese outpatients when 
compared to non-obese subjects from two separate 
control groups. This finding was consistent across all 
age groups but became less evident in the oldest 
group. Higher rates of use were primarily found for 
the local corticosteroids, in particular for the inhaled 
administration forms. In addition, we also found that 
a significantly higher percentage of the obese 
individuals were simultaneously using multiple 
corticosteroid types in comparison to non-obese 
subjects. However, no differences were observed with 
respect to oral corticosteroid use. 
 Cushing’s syndrome is most commonly induced 
by exogenous corticosteroid administration, typically 
attributed to (long-term) systemic corticosteroid use, 
and is frequently accompanied by weight gain [20, 
21]. However, the increased risk of occurrence of 
adrenal insufficiency even with local administration 
forms [16] shows the importance of surveillance for 
systemic effects of all administration types. We found 
that more than half of our obese sample have used 
corticosteroids at any point in time and that their 
recent use more often involves multiple 
administration routes, with the latter been strongly 
linked to supraphysiological systemic levels of 
glucocorticoids (based on high absolute risk of 
adrenal insufficiency) [16]. These findings tend to 
support our hypothesis that local corticosteroid 
forms, as being the most common prescribed agents in 
our obese group, could eventually contribute to 
amongst others a higher weight and/or a more 
laborious weight loss. But given the nature of this 
study, it is not possible to demonstrate temporality 
and to infer a causal relationship between 
corticosteroid use and obesity.  
 Regardless of the fact that in this study we did 
not assess the effect of corticosteroids on weight gain, 
physicians should be vigilant for 
corticosteroid-induced side effects in all patients 
gaining weight in a short period of time since 
approximately 10% of the marked weight gain in the 
ever corticosteroid users seemed to be preceded by 
corticosteroid use. In concordance with previous 
reports by Berthon et al, who showed that weight gain 
as a result of oral corticosteroids is unlikely in 
short-term users (<3 months) in contrast to long term 
users (≥3 months) [22, 23], majority of our 
corticosteroid induced marked weight gainers 
reported to have used corticosteroids for at least 
couple of months to several years. The cumulative 
exposure to corticosteroids seems therefore to be an 
essential factor in inducing weight changes. Since 
inhaled corticosteroids are generally prescribed for 
chronic conditions, and multiple type use most often 
includes inhaled agents, it is reasonable to 
hypothesize that these forms more gradually 
contribute to weight gain. The increasing prevalence 
of obesity [24] as well as increased corticosteroid use 
in the past decades [5, 8] additionally nourish the idea 
that corticosteroid use could be a substantial 




contributing factor for overall weight gain in the 
Western world. This is especially important given the 
fact that corticosteroids not only promote the 
accumulation of abdominal fat but also stimulate the 
appetite for high calorie “comfort” foods [12]. 
However, the cause-and-effect relationship 
between corticosteroid use and obesity seems to be 
bidirectional. Besides the well-known cardiometabolic 
diseases such as diabetes mellitus, dyslipidemia, and 
atherosclerosis, obesity has been linked to low-grade 
inflammation and various immune-mediated 
conditions [25, 26]. In the present study, we found 
that obese patients are using inhaled corticosteroids 
more frequently, which are mainly prescribed for 
asthma and chronic obstructive pulmonary disease 
(COPD). This is in line with literature where both 
conditions have been linked to higher BMI [27-29]. 
Interestingly, in a study with asthmatic obese 
patients, Van Huisstede et al. showed that weight loss 
after bariatric surgery was associated with improved 
asthma control and lower systemic inflammation 
markers [30]. Similar results were found in other 
studies in which weight loss was associated with less 
asthmatic symptoms and increased lung function [31, 
32]. In addition, weight loss and lower BMI have also 
been associated with reduced disease severity or 
better therapeutic response in other immune-related 
disorders including psoriasis [33, 34], rheumatoid 
arthritis [35, 36], and ankylosing spondylitis [37, 38]. 
This emphasizes the mentioned relationship between 
obesity and inflammation and could be an alternative 
reason for high corticosteroid use in our obese 
sample. Another plausible explanation would be that 
there is not a causal link between these parameters 
but that other factors, such as a low social-economic 
status and a pro-inflammatory genetic profile, lead to 
both obesity and more inflammation subsequently 
requiring the use of corticosteroids. 
 Nevertheless, it still remains disputable which of 
the two directions, i.e. corticosteroid use preceding 
obesity or vice versa, prevails in clinical practice. 
Patients with COPD, for instance, commonly present 
with overweight or obesity [39]. Since corticosteroids 
are an important part of the medical treatment of 
COPD, it could be proposed that the overall high BMI 
in these patients is partly the result of corticosteroid 
use. Aside from the reverse causality between these 
characteristics, it would be advisable to screen all 
obese patients for corticosteroid use. In the case of 
corticosteroid use, one should reconsider if the use is 
still necessary and if so, whether an alternative 
treatment is available. The importance of this can be 
derived from a previous study in asthmatic obese 
patients for whom the diagnosis could not be 
confirmed in 41% of the cases after extensive 
pulmonary testing, although 23% of these patients 
were still currently using inhaled corticosteroids [40]. 
In these cases, ceasing of corticosteroids under 
medical supervision could potentially help in losing 
weight more easily. Otherwise, patients may succumb 
to a vicious cycle of weight gain, obesity-related 
comorbidities, and further corticosteroid need.  
 One of the strengths of the present study is the 
use of two different non-obese control groups and the 
fact that both the study group and the control groups 
are from the same country. Moreover, the same 
detailed questionnaire on corticosteroid use was 
administered in both non-obese cohorts.  
 An important study limitation worth noting is 
that information about the dose and duration of 
corticosteroid use was incomplete and hence not used 
in this study. Both components are known to play an 
important role in the accumulative exposure and 
induction of side effects in corticosteroid users [41]. 
Nevertheless, medical conditions requiring 
corticosteroids are most often of a chronic nature and 
demand corticosteroid use for a longer period of time 
or at least with frequent intervals. Moreover, various 
studies have shown that weight gain can also occur in 
response to relatively low doses of corticosteroids. In 
a study of more than two thousand long-term 
corticosteroid users, Curtis et al. have found that 
weight gain manifested in 70% of the low-dose 
systemic users and was indeed the most prevalent 
self-reported adverse event [11].  
In conclusion, corticosteroid use is high in obese 
individuals who have been referred due to their 
obesity and common across all ages. High user rates 
were especially prevalent for inhaled corticosteroids 
and the simultaneous use of different administration 
forms. This warrants stricter monitoring of 
corticosteroid use in obese as these medications can 
potentially induce weight gain and maintain excess 
weight. However, large longitudinal prospective 
cohort studies are needed to specifically determine 
the individual effect of the different corticosteroid 
administration forms on weight gain. 
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